Castle Biosciences Inc

NASDAQ:CSTL 4:00:00 PM EDT

21.42

-1.33 (-5.85%)

: $21.40 -0.02 (-0.09%)

Market Cap (Intraday)	585.01M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$71.22 Million
Adjusted EPS	-$0.53

See more estimates

10-Day MA	$22.54
50-Day MA	$19.74
200-Day MA	$22.04

See more pivots

Castle Biosciences Inc Stock, NASDAQ:CSTL

505 South Friendswood Drive, Suite 401, Friendswood, Texas 77546

United States of America

Phone: +1.866.788.9007

Number of Employees: 761

http://www.castlebiosciences.com

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.